NASDAQ Framework: Vaxcyte Inc.
Clinical-stage biotechnology vaccine company 1.
1: Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. View Source
Vaxcyte, Inc., headquartered in San Carlos, California, is a clinical-stage biotechnology vaccine company focused on developing novel protein vaccines to prevent or treat bacterial infectious diseases. Incorporated in 2013 and formerly known as SutroVax, Inc., the company changed its name to Vaxcyte, Inc. in May 2020. Its lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. Additionally, Vaxcyte is developing other vaccine candidates, including VAX-31 to combat emerging strains and antibiotic resistance, VAX-A1 for Group A Streptococcus, VAX-PG targeting periodontitis, and VAX-GI to prevent Shigella infections 2.
2: Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. View Source
UNKNOWN
The provided facts do not contain any information regarding whether Vaxcyte Inc. is still led by its founders or if the founders are heavily involved in the company.
The provided facts do not contain any information regarding whether Vaxcyte Inc. is still led by its founders or if the founders are heavily involved in the company.
MEDIUM RISK
Vaxcyte Inc. is a clinical-stage biotechnology company, which implies that it is not yet generating revenue from product sales and is likely reliant on external funding to support its operations. While the company has promising vaccine candidates and has completed significant milestones such as the enrollment of a Phase 2 study for VAX-24 3, insider sales by key executives such as the COO and SVP of Finance 4 could indicate potential concerns about the company's short-term financial outlook. Additionally, the company has received positive ratings from various analysts, with price targets suggesting confidence in its future prospects 5. However, the lack of detailed financial data in the provided facts makes it difficult to definitively assess the company's ability to cover its costs and spending plans in the coming 12-18 months, placing it in a medium risk category.
Vaxcyte Inc. is a clinical-stage biotechnology company, which implies that it is not yet generating revenue from product sales and is likely reliant on external funding to support its operations. While the company has promising vaccine candidates and has completed significant milestones such as the enrollment of a Phase 2 study for VAX-24 3, insider sales by key executives such as the COO and SVP of Finance 4 could indicate potential concerns about the company's short-term financial outlook. Additionally, the company has received positive ratings from various analysts, with price targets suggesting confidence in its future prospects 5. However, the lack of detailed financial data in the provided facts makes it difficult to definitively assess the company's ability to cover its costs and spending plans in the coming 12-18 months, placing it in a medium risk category.
3: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants View Source4: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 4.96 percent of Vaxcyte Inc shares are owned by insiders, and 106.12 percent are held by financial institutions. Cowan Elvia, the SVP, FINANCE at Vaxcyte Inc (PCVX) has sold 5,000 shares of firm on Jul 16 ’24 at a price of $85.00 against the total amount of $0.42 million. In another inside trade, Cowan Elvia, SVP, FINANCE of Vaxcyte Inc (NASDAQ:PCVX) sold 5,000 shares of the firm on Jul 08 ’24 for a total worth of $0.4 million at a price of $80.00. An inside trade which took place on Jul 01 ’24, CHIEF OPERATING OFFICER of Vaxcyte Inc Wassil Jim sold 3,000 shares of firm against total price of $0.23 million at the cost of $76.34 per share. View Source5: Mizuho raised the price target for the Vaxcyte Inc (NASDAQ:PCVX) stock to “a Buy”. The rating was released on December 07, 2023, according to finviz. The research report from Needham has reiterated the stock to Buy, with a price target set at $58. The stock was initiated by Guggenheim, who disclosed in a research note on December 15, 2022, to Buy and set the price objective to $66. In their research brief published November 17, 2022, BTIG Research analysts initiated the Vaxcyte Inc stock to Buy with a price target of $69. View Source
6: Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. View Source7: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants View Source
Vaxcyte Inc.'s product roadmap for 2024 through to 2026 focuses on advancing its portfolio of novel protein vaccines aimed at preventing or treating bacterial infectious diseases. The company is progressing with its lead vaccine candidate, VAX-24, a 24-valent investigational pneumococcal conjugate vaccine, having completed the enrollment of a Phase 2 study for the prevention of invasive pneumococcal disease in infants 8. Additionally, Vaxcyte is developing VAX-31 to address emerging strains and antibiotic resistance, VAX-A1 for Group A Streptococcus, VAX-PG targeting periodontitis, and VAX-GI to prevent Shigella infections 9. These efforts underscore Vaxcyte's commitment to expanding its vaccine pipeline and addressing significant global health challenges.
8: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants View Source9: Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. View Source